Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Receivables: 2014-2020

Historic Change in Receivables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 7 years, with Dec 2020 value amounting to -$48,000.

  • Viridian Therapeutics, Inc.\DE's Change in Receivables rose 94.49% to -$48,000 in Q4 2020 from the same period last year, while for Dec 2020 it was -$99,000, marking a year-over-year decrease of 217.86%. This contributed to the annual value of -$99,000 for FY2020, which is 217.86% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Change in Receivables of -$48,000 as of Q4 2020, which was up 74.87% from -$191,000 recorded in Q3 2020.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Change in Receivables peaked at $3.4 million during Q1 2018, and registered a low of -$3.6 million during Q2 2018.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Change in Receivables value was -$33,000 (recorded in 2019), while the average stood at -$120,583.
  • Its Change in Receivables has fluctuated over the past 5 years, first tumbled by 2,044.12% in 2016, then spiked by 7,363.64% in 2017.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Change in Receivables (Quarterly) stood at $11,000 in 2016, then skyrocketed by 7,363.64% to $821,000 in 2017, then slumped by 265.41% to -$1.4 million in 2018, then skyrocketed by 35.86% to -$871,000 in 2019, then skyrocketed by 94.49% to -$48,000 in 2020.
  • Its last three reported values are -$48,000 in Q4 2020, -$191,000 for Q3 2020, and $244,000 during Q2 2020.